补体因子 B 抑制剂 iptacopan 通过基于补体的免疫调节驱动胰腺癌微环境的抗肿瘤作用
Complement factor B blockade by iptacopan drives antitumor complement-based immunomodulation in pancreatic cancer microenvironment.
肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文。默认按评分排序(权威性 + 新鲜度)。
Complement factor B blockade by iptacopan drives antitumor complement-based immunomodulation in pancreatic cancer microenvironment.
CD73 is associated with glycolysis related metabolic programs and CD8(+) T cell suppression in pancreatic ductal adenocarcinoma.
A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca(17)Mab-5, for Multiple Applications.
Ca 17 Mab-5 是检测 CDH17 的多功能工具,具有肿瘤诊断的潜力。
Biological Borderline Resectable Pancreatic Cancer Represents a Genetically and Immunologically Aggressive Subtype: A Retrospective Study.
术前 CA19-9 升高可识别出一个生物学侵袭性强的 PDAC 亚群,该亚群具有基因组改变增加和免疫抑制微环境。将 CA19-9 ≥500 U/mL 视为高风险疾病的标志物,可能有助于指导强化围手术期策略,即使在影像学判定为可切除的病例中也是如此。
Combined assessment of stromal tumor infiltrating lymphocytes and tumor peroxiredoxin 4 expression improved prognostic stratification in postoperative
基质 TIL 和 PRDX4 似乎分别捕捉了 PC 的免疫和氧化还原互补特征。它们的联合评估可能改善预后分层,并有助于识别一个潜在的氧化还原相关、免疫排斥亚组,该亚组预后特别差。
Tumor-reactive TCRs within exhausted TILs reveal cancer type-specific immune landscapes in renal cell carcinoma.
Strategies to Target the Tumor-Associated Macrophages in the Immunosuppressive Microenvironment of Pancreatic Ductal Adenocarcinoma.
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1
在治疗前表现出 WT1 特异性细胞和体液免疫自发激活的 UR-PDAC 患者中,内源性 WT1 特异性 CD8+Tn 细胞通过 WT1 靶向化学免疫疗法被工程化为 WT1 特异性记忆 CD8+细胞,从而产生了更优的治疗效果。WT1 靶向化学免疫疗法还通过表位扩展诱导了新抗原特异性免疫反应,导致表达新抗原的 PDAC 细胞被消除,并带来了良好的临床结局。
Stromal modifying CHST15 siRNA enhances antitumor effect synergistically with anti-PD-1 immune checkpoint antibody in murine pancreatic cancer.
Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression.
MEMBER ACCOUNT
登录成功会直接打开下一页。